Capital Allocation Strategies Drive Diverging Fortunes as Pharma Companies Invest in Growth While IT Firms Focus on Shareholder Payouts
For decades, India's Information Technology sector was considered the crown jewel of the country's corporate landscape. Global demand for software services, strong cash flows, and consistent dividend payouts helped IT companies generate substantial wealth for investors. However, over the past five years, a surprising trend has emerged: pharmaceutical companies have significantly outperformed their IT counterparts despite both sectors benefiting from similar macroeconomic tailwinds.
According to market expert Harini Dedhia, the answer lies not in market cycles or currency movements but in how companies chose to deploy their profits. The comparison between the Nifty Pharma and Nifty IT indices highlights a critical investing lesson—long-term wealth creation often depends more on reinvestment than on immediate shareholder rewards.
As the business environment evolves rapidly with the rise of artificial intelligence, biotechnology, and digital transformation, capital allocation decisions are becoming increasingly important in determining future winners and losers.
A Tale of Two Sectors
Both the pharmaceutical and IT sectors are among India's largest export-oriented industries. Both benefit when the Indian rupee weakens against global currencies, and both operate in highly competitive international markets.
Yet their stock market performances over the past five years tell very different stories.
Five-Year Performance Comparison
-
Nifty Pharma CAGR: 12.4%
-
Nifty IT CAGR: -0.85%
The divergence is striking, particularly considering that both industries were exposed to similar macroeconomic conditions.
Analysts believe the explanation lies in management decisions regarding profit allocation and future investments.
The Importance of Capital Allocation
Every profitable company faces a fundamental decision regarding how to use the cash it generates.
Management teams can choose to:
-
Return money to shareholders through dividends
-
Repurchase shares through buybacks
-
Reinvest in business expansion
-
Fund research and innovation
-
Pursue acquisitions
-
Build new capabilities
The choice often determines whether a company remains competitive in the future.
Why Reinvestment Matters
Reinvestment allows businesses to:
-
Expand operations
-
Develop new products
-
Improve efficiency
-
Enter new markets
-
Build competitive advantages
-
Generate higher future earnings
Companies that consistently earn high returns on reinvested capital often become long-term wealth creators.
IT Sector Prioritised Shareholder Returns
According to the analysis, India's IT companies allocated a substantial portion of profits toward shareholder distributions.
Where IT Profits Went
Since FY18:
-
Approximately 85% of profits were returned via dividends and buybacks
-
Less than 15% was reinvested into future growth initiatives
-
Only around 1.9% of profits were directed toward research and development
This strategy made IT stocks attractive for income-focused investors but may have limited their ability to adapt to rapidly changing technology trends.
While dividends provide immediate returns, they do not necessarily create future earnings growth.
Pharma Companies Took a Different Path
The pharmaceutical sector adopted an almost opposite approach.
Instead of distributing the majority of profits, pharma companies aggressively reinvested earnings back into their businesses.
Pharma's Reinvestment Strategy
Since FY16:
-
Only 26.5% of profits were distributed to shareholders
-
More than 105% of profits were reinvested
-
Nearly 40% of profits were allocated to R&D activities
This investment-focused strategy enabled pharmaceutical companies to expand manufacturing capabilities, develop new products, and strengthen their global competitiveness.
Research and Development Became a Growth Engine
One of the biggest differentiators between the two sectors has been spending on research and development.
Innovation remains the lifeblood of the pharmaceutical industry.
Developing new medicines, specialty products, biologics, and complex generics requires substantial investment and long development cycles.
Why R&D Creates Value
Research investments help pharmaceutical companies:
-
Launch new therapies
-
Expand product pipelines
-
Enter regulated markets
-
Improve margins
-
Extend growth visibility
-
Strengthen intellectual property portfolios
Although R&D spending can reduce short-term profitability, it often creates significant long-term value.
Earnings Growth Reflects Reinvestment Success
Ultimately, stock prices tend to follow earnings growth over time.
The superior reinvestment strategy adopted by pharma companies has translated into stronger profit growth.
Profit Growth Comparison
Five-Year PAT CAGR:
-
Nifty Pharma: 11.2%
-
Nifty IT: 8.5%
While both sectors achieved earnings growth, pharmaceutical companies generated stronger and more consistent expansion.
The difference in earnings performance largely explains the divergence in stock market returns.
Pharma's Growth Is Accelerating
Perhaps the most important observation is that pharmaceutical companies are not just growing—they are accelerating.
The sector's profit growth trajectory shows:
-
Three-year growth exceeding five-year growth
-
Five-year growth exceeding ten-year growth
This suggests that earlier investments are beginning to generate increasingly larger returns.
The Compounding Effect
Successful reinvestment creates a powerful cycle:
-
Invest in growth
-
Generate higher earnings
-
Reinvest larger profits
-
Expand future earnings potential
This positive feedback loop is one of the most powerful drivers of long-term shareholder wealth creation.
IT Faces a New Reality in the AI Era
The rise of artificial intelligence has highlighted some of the challenges facing traditional IT services companies.
Many analysts believe that the sector may have underinvested in:
-
Proprietary technology
-
AI capabilities
-
Product innovation
-
Advanced software platforms
-
Automation solutions
The emergence of Generative AI has forced companies to accelerate investments that perhaps should have begun earlier.
AI Could Trigger a New Investment Cycle
The current technological transformation may encourage IT firms to:
-
Increase R&D spending
-
Build AI platforms
-
Develop proprietary solutions
-
Invest in talent and innovation
If executed successfully, this could support a future revival in growth and profitability.
Why Investors Should Pay Attention
The comparison between pharma and IT offers a broader lesson that applies across sectors.
Investors often focus on:
-
Dividend yields
-
Buyback announcements
-
Short-term earnings
However, long-term returns are frequently driven by a company's ability to reinvest capital at attractive rates.
Characteristics of Strong Reinvestment Businesses
Companies that create sustainable wealth often:
-
Reinvest consistently
-
Prioritize innovation
-
Build competitive advantages
-
Expand addressable markets
-
Generate improving returns on capital
These qualities can drive superior earnings growth over long periods.
India's Pharma Industry Benefits From Multiple Tailwinds
The pharmaceutical sector's strong performance is also supported by favorable industry dynamics.
Growth drivers include:
-
Rising global healthcare spending
-
Aging populations
-
Demand for affordable medicines
-
Expansion of specialty products
-
Contract manufacturing opportunities
-
Increasing exports
Combined with strong reinvestment strategies, these trends have created a favorable environment for sustained growth.
Outlook: Reinvestment May Continue to Define Future Winners
As industries become increasingly technology-driven and competitive, companies that invest in future capabilities are likely to gain an advantage over those focused solely on returning cash to shareholders.
The success of the pharmaceutical sector demonstrates how reinvestment can strengthen earnings growth, accelerate innovation, and create long-term shareholder value.